福元医药：氨氯地平贝那普利胶囊获得药品注册证书

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) has received the drug registration certificate from the National Medical Products Administration for Amlodipine Benazepril Capsules, indicating a significant milestone for the company in the hypertension treatment market [1]. Group 1: Product Approval - The National Medical Products Administration has issued a drug registration certificate for Amlodipine Benazepril Capsules, which contain 5mg of Amlodipine and 10mg of Benazepril per capsule [1]. - This product is intended for patients whose blood pressure is not adequately controlled by either Amlodipine or Benazepril alone, or for those who are switching from separate Amlodipine and Benazepril tablets [1]. Group 2: Market Context - Amlodipine Benazepril was originally developed by Novartis and was first approved in the United States in March 1995 [1]. - The original manufacturer’s version of Amlodipine Benazepril has not yet been launched in China, presenting a potential market opportunity for Fuyuan Pharmaceutical [1].